A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates

J Infect Dis. 1994 Apr;169(4):879-82. doi: 10.1093/infdis/169.4.879.

Abstract

A rapid screening test for antiviral susceptibility to acyclovir and foscarnet was evaluated in 320 herpes simplex virus (HSV) isolates from 197 patients. Of the isolates tested (16% HSV-1, 84% HSV-2), 60% were resistant in vitro to acyclovir and 5% were resistant to foscarnet using the plaque reduction assay. The rapid screening test, requiring only 3 days to yield a preliminary susceptibility result, was highly associated with the results of the plaque reduction assay for acyclovir and foscarnet (P < or = .001 for each) and with the clinical response to antiviral therapy (P < .001, P = .001, respectively).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyclovir / pharmacology*
  • Acyclovir / therapeutic use
  • Animals
  • Drug Resistance, Microbial
  • Evaluation Studies as Topic
  • Foscarnet / pharmacology*
  • Foscarnet / therapeutic use
  • Herpes Genitalis / drug therapy
  • Herpes Genitalis / microbiology
  • Herpes Simplex / drug therapy
  • Herpes Simplex / microbiology
  • Herpesvirus 1, Human / drug effects*
  • Herpesvirus 2, Human / drug effects*
  • Humans
  • Microbial Sensitivity Tests* / methods
  • Neutralization Tests
  • Sensitivity and Specificity
  • Time Factors
  • Vero Cells

Substances

  • Foscarnet
  • Acyclovir